An analysis of over 22,000 FDA adverse event reports found that injectable semaglutide is more likely to cause endocrine side effects while oral semaglutide is more likely to cause gastrointestinal problems and triggers reactions faster.
22,287 adverse event reportsAnalyzed from the FDA's FAERS database over six years, revealing distinct side effect profiles for injectable vs. oral semaglutide
What the researchers found
Analysis of 22,287 adverse event reports from the FDA's FAERS database revealed distinct side effect profiles depending on whether semaglutide was given by injection or taken orally. Subcutaneous injection was more likely to cause endocrine-related adverse events, while oral semaglutide was more likely to trigger gastrointestinal side effects.
Notably, oral administration also accelerated the onset of adverse reactions compared to injection. The study compared 16,346 subcutaneous injection reports against 2,496 oral administration reports from Q4 2017 through Q4 2023.
Why it matters
Millions of people now take semaglutide for diabetes or weight loss, and they often have a choice between injectable (Ozempic/Wegovy) and oral (Rybelsus) forms. Understanding that these routes carry different side effect profiles — not just different convenience levels — helps doctors and patients make more informed treatment decisions.
The numbers in context
22,287 total adverse event reports · 16,346 subcutaneous reports · 2,496 oral reports · Q4 2017–Q4 2023
How the study worked
Retrospective pharmacovigilance study analyzing real-world adverse event data from the FDA Adverse Event Reporting System (FAERS). Researchers used disproportionality analysis and reporting odds ratios (ROR) to compare adverse event signals between subcutaneous and oral semaglutide, along with stratified analysis and time-to-onset assessment.
Who was studied
22,287 adverse event reports from patients taking semaglutide (subcutaneous or oral) reported to the FDA from 2017 to 2023
What this study cannot tell us
FAERS data is voluntarily reported and may be incomplete or biased toward more severe reactions. Reporting rates don't equal true incidence rates. The study cannot establish causation, only statistical associations. The oral semaglutide group was substantially smaller (2,496 vs. 16,346 reports), which may affect comparisons.
How to read the evidence
This is a moderate-grade pharmacovigilance study using real-world FDA adverse event data. While it captures a large volume of reports, FAERS data is voluntarily submitted and cannot establish incidence rates or causation like a controlled trial would.
When this study was published
Published in 2024 with data through Q4 2023, this study reflects the most current available adverse event reporting for both semaglutide formulations.
The bigger picture
As GLP-1 drugs become some of the most prescribed medications worldwide, understanding the real-world safety differences between delivery methods is critical. This data suggests the choice between injection and pill isn't just about convenience — it may meaningfully affect which side effects patients experience and how quickly they appear.
Questions still open
- Do the endocrine side effects seen more often with injectable semaglutide reflect higher systemic drug levels compared to oral dosing?
- Would slower dose titration of oral semaglutide reduce the faster onset of gastrointestinal side effects?
- Do these route-dependent side effect differences also apply to other GLP-1 drugs being developed in oral forms like orforglipron?
Common questions
Does oral semaglutide cause more side effects than the injection?
What is the FAERS database and how reliable is it?
Read the original research
Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system.
Frontiers in pharmacology, 15, 1414268
Citation
Niu, Kaibin; Fan, Maoxia; Gao, Wulin; Chen, Chen; Dai, Guohua. (2024). Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system.. Frontiers in pharmacology, 15, 1414268. https://doi.org/10.3389/fphar.2024.1414268